Hyporesponsiveness to anemia therapy--what are we doing wrong?
Most patients receiving anemia therapy respond well, with a significant rise in hemoglobin concentration. However, approximately 5%-10% of patients fail to show a satisfactory response despite high doses of erythropoietin. The definition of hyporesponsiveness to anemia therapy is somewhat arbitrary, but it is generally regarded as a failure to achieve a hemoglobin concentration of 10-11 g/dL despite a dose of erythropoietin in excess of 200 U/kg weekly. The condition has many causes, the most important ones being iron deficiency, infection or inflammation, and underdialysis. Investigating a patient's poor response to erythropoietin should begin with a check for compliance, followed by screening for iron deficiency. If doubt exists about the presence of iron deficiency, then a trial of intravenous iron may be given. A reticulocyte count may be helpful. A significantly elevated count suggests the presence of blood loss or hemolysis. The level of C-reactive protein (CRP) may be useful as an indicator of underlying inflammation, and underdialysis may be corrected by increasing the dialysis prescription. If other, minor causes of hyporesponsiveness to erythropoietin have been excluded, then a bone marrow biopsy should be performed. Some patients may require higher doses of erythropoietin, and it is not unreasonable to increase the dose to 10,000 U thrice weekly. Some causes of hyporesponsiveness to erythropoietin, such as iron deficiency and underdialysis, are easily corrected; but others, such as primary bone marrow disorders and hemoglobinopathies, are not possible to overcome.
MacDougall
I C
IC
Department of Renal Medicine, King's College Hospital, London, UK. icm-kru@globalnet.co.uk
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy; D001424:Bacterial Infections / Q000150:complications; D002097:C-Reactive Protein / Q000032:analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010349:Patient Compliance; D010530:Peritoneal Dialysis / Q000009:adverse effects; D011994:Recombinant Proteins; D017701:Reticulocyte Count; D017211:Treatment Failure
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D002097:C-Reactive Protein